Terms: = Germ cell tumor AND EPAS1, MOP2, 2034, ENSG00000116016, PASD2, HIF2A, Q99814 AND Treatment
31 results:
1. Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy.
Atkinson TM; Hay JL; Young Kim S; Schofield E; Postow MA; Momtaz P; Warner AB; Shoushtari AN; Callahan MK; Wolchok JD; Li Y; Chapman PB
Oncologist; 2023 Apr; 28(4):351-357. PubMed ID: 36745014
[TBL] [Abstract] [Full Text] [Related]
2. Comprehensive
Karaghiannis V; Maric D; Garrec C; Maaziz N; Buffet A; Schmitt L; Antunes V; Airaud F; Aral B; Le Roy A; Corbineau S; Mansour-Hendili L; Lesieur V; Rimbert A; Laporte F; Delamare M; Rab M; Bézieau S; Cassinat B; Galacteros F; Gimenez-Roqueplo AP; Burnichon N; Cario H; Van Wijk R; Bento C; Girodon F; Hoogewijs D; Gardie B
Haematologica; 2023 Jun; 108(6):1652-1666. PubMed ID: 36700397
[TBL] [Abstract] [Full Text] [Related]
3. Targeted Therapies in Pheochromocytoma and Paraganglioma.
Wang K; Crona J; Beuschlein F; Grossman AB; Pacak K; Nölting S
J Clin Endocrinol Metab; 2022 Nov; 107(11):2963-2972. PubMed ID: 35973976
[TBL] [Abstract] [Full Text] [Related]
4. Preclinical evaluation of targeted therapies in Sdhb-mutated tumors.
Moog S; Salgues B; Braik-Djellas Y; Viel T; Balvay D; Autret G; Robidel E; Gimenez-Roqueplo AP; Tavitian B; Lussey-Lepoutre C; Favier J
Endocr Relat Cancer; 2022 May; 29(6):375-388. PubMed ID: 35348472
[TBL] [Abstract] [Full Text] [Related]
5. Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures.
Wang K; Schütze I; Gulde S; Bechmann N; Richter S; Helm J; Lauseker M; Maurer J; Reul A; Spoettl G; Klink B; William D; Knösel T; Friemel J; Bihl M; Weber A; Fankhauser M; Schober L; Vetter D; Broglie Däppen M; Ziegler CG; Ullrich M; Pietzsch J; Bornstein SR; Lottspeich C; Kroiss M; Fassnacht M; Wenter VUJ; Ladurner R; Hantel C; Reincke M; Eisenhofer G; Grossman AB; Pacak K; Beuschlein F; Auernhammer CJ; Pellegata NS; Nölting S
Endocr Relat Cancer; 2022 May; 29(6):285-306. PubMed ID: 35324454
[TBL] [Abstract] [Full Text] [Related]
6. Belzutifan, a Potent HIF2α Inhibitor, in the Pacak-Zhuang Syndrome.
Kamihara J; Hamilton KV; Pollard JA; Clinton CM; Madden JA; Lin J; Imamovic A; Wall CB; Wassner AJ; Weil BR; Heeney MM; Vargas SO; Kaelin WG; Janeway KA; Perini RF; Zojwalla NJ; Voss SD; DuBois SG
N Engl J Med; 2021 Nov; 385(22):2059-2065. PubMed ID: 34818480
[TBL] [Abstract] [Full Text] [Related]
7. Personalized Management of Pheochromocytoma and Paraganglioma.
Nölting S; Bechmann N; Taieb D; Beuschlein F; Fassnacht M; Kroiss M; Eisenhofer G; Grossman A; Pacak K
Endocr Rev; 2022 Mar; 43(2):199-239. PubMed ID: 34147030
[TBL] [Abstract] [Full Text] [Related]
8. Systematic review and meta-analysis of local recurrence rates of head and neck cutaneous melanomas after wide local excision, Mohs micrographic surgery, or staged excision.
Bittar PG; Bittar JM; Etzkorn JR; Brewer JD; Aizman L; Shin TM; Sobanko JF; Higgins HW; Giordano CN; Cohen JV; Pride R; Wan MT; Leitenberger JJ; Bar AA; Aasi S; Bordeaux JS; Miller CJ
J Am Acad Dermatol; 2021 Sep; 85(3):681-692. PubMed ID: 33961921
[TBL] [Abstract] [Full Text] [Related]
9. Pseudohypoxic pheochromocytomas and paragangliomas dominate in children.
Redlich A; Pamporaki C; Lessel L; Frühwald MC; Vorwerk P; Kuhlen M
Pediatr Blood Cancer; 2021 Jul; 68(7):e28981. PubMed ID: 33682326
[TBL] [Abstract] [Full Text] [Related]
10. The VHL/HIF Axis in the Development and treatment of Pheochromocytoma/Paraganglioma.
Peng S; Zhang J; Tan X; Huang Y; Xu J; Silk N; Zhang D; Liu Q; Jiang J
Front Endocrinol (Lausanne); 2020; 11():586857. PubMed ID: 33329393
[TBL] [Abstract] [Full Text] [Related]
11. METTL3 potentiates resistance to cisplatin through m
Wei J; Yin Y; Zhou J; Chen H; Peng J; Yang J; Tang Y
J Cell Mol Med; 2020 Oct; 24(19):11366-11380. PubMed ID: 32857912
[TBL] [Abstract] [Full Text] [Related]
12. ARNT-dependent HIF-2 transcriptional activity is not sufficient to regulate downstream target genes in neuroblastoma.
Persson CU; von Stedingk K; Fredlund E; Bexell D; Påhlman S; Wigerup C; Mohlin S
Exp Cell Res; 2020 Mar; 388(2):111845. PubMed ID: 31945318
[TBL] [Abstract] [Full Text] [Related]
13. Postoperative Hearing Preservation in Patients Undergoing Retrosigmoid Craniotomy for Resection of Vestibular Schwannomas: A Systematic Review of 2034 Patients.
Preet K; Ong V; Sheppard JP; Udawatta M; Duong C; Romiyo P; Nguyen T; Kwan I; Yang I
Neurosurgery; 2020 Mar; 86(3):332-342. PubMed ID: 31149722
[TBL] [Abstract] [Full Text] [Related]
14. Collaborative ISL1/GATA3 interaction in controlling neuroblastoma oncogenic pathways overlapping with but distinct from MYCN.
Zhang Q; Zhang Q; Jiang X; Ye Y; Liao H; Zhu F; Yan J; Luo L; Tian L; Jiang C; Chen Y; Liang X; Sun Y
Theranostics; 2019; 9(4):986-1000. PubMed ID: 30867811
[No Abstract] [Full Text] [Related]
15. epas1/HIF2α correlates with features of low-risk neuroblastoma and with adrenal chromaffin cell differentiation during sympathoadrenal development.
Westerlund I; Shi Y; Holmberg J
Biochem Biophys Res Commun; 2019 Jan; 508(4):1233-1239. PubMed ID: 30563765
[TBL] [Abstract] [Full Text] [Related]
16. Wnt Signalling Drives Context-Dependent Differentiation or Proliferation in Neuroblastoma.
Szemes M; Greenhough A; Melegh Z; Malik S; Yuksel A; Catchpoole D; Gallacher K; Kollareddy M; Park JH; Malik K
Neoplasia; 2018 Apr; 20(4):335-350. PubMed ID: 29505958
[TBL] [Abstract] [Full Text] [Related]
17. PHEOCHROMOCYTOMA: A GENETIC AND DIAGNOSTIC UPDATE.
Mercado-Asis LB; Wolf KI; Jochmanova I; Taïeb D
Endocr Pract; 2018 Jan; 24(1):78-90. PubMed ID: 29144820
[TBL] [Abstract] [Full Text] [Related]
18. HIF-2alpha: Achilles' heel of pseudohypoxic subtype paraganglioma and other related conditions.
Tella SH; Taïeb D; Pacak K
Eur J Cancer; 2017 Nov; 86():1-4. PubMed ID: 28946040
[TBL] [Abstract] [Full Text] [Related]
19. New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas.
Toledo RA
Endocr Relat Cancer; 2017 Sep; 24(9):C9-C19. PubMed ID: 28667082
[TBL] [Abstract] [Full Text] [Related]
20. Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway.
Pang Y; Yang C; Schovanek J; Wang H; Bullova P; Caisova V; Gupta G; Wolf KI; Semenza GL; Zhuang Z; Pacak K
Oncotarget; 2017 Apr; 8(14):22313-22324. PubMed ID: 28423608
[TBL] [Abstract] [Full Text] [Related]
[Next]
